What the results of Wegovy’s longest clinical trial yet show about ...
May 13, 2024 · More than 25,000 people in the US are starting Wegovy every week, drugmaker Novo Nordisk said this month. And in a KFF poll released Friday, 6% of respondents said they were currently using a...
News details - Novo Nordisk
PLAINSBORO, N.J., March 8, 2024 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Wegovy ® to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight along ...
Novo Nordisk shares jump 8% after Wegovy sales beat …
Nov 6, 2024 · Novo Nordisk on Wednesday reported a third-quarter beat on sales of its blockbuster weight-loss drug Wegovy and narrowed its 2024 full-year growth guidance. Company shares jumped early on...
News Details - Novo Nordisk
Mar 8, 2024 · "We are very pleased that Wegovy ® is now approved in the US as the first therapy to help people manage their weight and reduce cardiovascular risks," said Martin Holst Lange, executive vice president and head of Development at Novo Nordisk.
News Details - Novo Nordisk
Jul 25, 2024 · The SELECT trial demonstrated that Wegovy ® statistically significantly reduced the risk of MACE by 20% compared to placebo when added to standard of care.
News details - Novo Nordisk
PLAINSBORO, NJ, December 23, 2022 – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Wegovy ® (semaglutide) injection 2.4 mg, making it the first-and-only prescription anti …
Novo's Wegovy shows heart benefit alongside weight loss in trial
COPENHAGEN/LONDON, Aug 8 (Reuters) - Wegovy maker Novo Nordisk (NOVOb.CO) said on Tuesday a large study had shown the highly effective obesity treatment also had a clear cardiovascular...
News details - Novo Nordisk
PLAINSBORO, N.J., June 4, 2021 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Wegovy ™ (semaglutide) injection 2.4 mg, the first-and-only prescription weight-loss …
News Details - Novo Nordisk
Nov 11, 2021 · “With the unprecedented and sustained weight loss for an anti-obesity medication, Wegovy™ has the potential to transform obesity management and help millions of people living with obesity,” said Martin Holst Lange, executive vice president, Development at Novo Nordisk.
Novo Nordisk says Wegovy is more available after supply boost - NBC News
Jan 31, 2024 · Novo Nordisk said Wednesday that it has increased the supply of the lowest dose of its blockbuster weight loss drug Wegovy, which it says will allow more people in the U.S. to start taking...